FindTrial
Sign In

Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to paclitaxel in Upper gastrointestinal tumors

Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to paclitaxel in Upper gastrointestinal tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-11001736
Enrollment
Unknown
Registered
2011-11-22
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper gastrointestinal tumors

Interventions

Paclitaxel treatment group:paclitaxel175mg/m2

Sponsors

Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18 years old to 75 years old; Survival time is expected to more than 3 months; KPS score more than 70 points; There is a clear pathology diagnosis; No contraindications to chemotherapy.Have imaging confirmed lesions

Exclusion criteria

Exclusion criteria: Less than 3 month period is expected to survive; With severe basic diseases; Have chemotherapy contraindications; No imaging can be assessed lesions.

Design outcomes

Primary

MeasureTime frame
response rate;—

Countries

China

Contacts

Public ContactChushu Ji
jichushu@csco.org.cn+86 13955116062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026